[Erectile dysfunction: conservative treatment and new approaches].

Area of Science:

• Urology
• Cardiology
• Pharmacology

Background:

• Erectile dysfunction (ED) is increasingly discussed, with strong links to cardiovascular disease, suggesting it as an early vascular disorder indicator.
• Phosphodiesterase type 5 (PDE-5) inhibitors have transformed ED treatment, offering well-tolerated and effective first-line options.

Purpose of the Study:

• To review the current therapeutic landscape for erectile dysfunction.
• To highlight the efficacy and limitations of PDE-5 inhibitors.
• To explore novel and emerging treatments for refractory ED cases.

Main Methods:

• Review of current literature on erectile dysfunction treatments.
• Analysis of the role of PDE-5 inhibitors in managing ED.
• Investigation into alternative and experimental therapies for difficult-to-treat ED.

Main Results:

• PDE-5 inhibitors (sildenafil, vardenafil, tadalafil) are effective first-line treatments for ED, with reviewed cardiac and vascular effects.
• Approximately 30% of patients require alternative therapies beyond PDE-5 inhibitors.
• Intracavernous injections represent a successful second-line treatment for ED.

Conclusions:

• While PDE-5 inhibitors are revolutionary, a significant portion of patients need alternative ED treatments.
• Emerging therapies like gene transfer, stem cells, melanocortin activators, and shockwave therapy show promise for refractory ED.
• Continued research into novel approaches is crucial for managing difficult-to-treat erectile dysfunction.